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Abstract
RalA and RalB are members of the Ras family of small G proteins and are activated downstream of Ras via RalGEFs. The RalGEF-Ral axis represents one of the major effector pathways controlled by Ras and as such is an important pharmacological target. RalA and RalB are approximately 80% identical at the amino acid level; despite this they have distinct roles both in normal cells and in the disease state. We have used our structure of RalB-RLIP76 to guide an analysis of Ral-effector interaction interfaces, creating panels of mutant proteins to probe the energetics of these interactions. The data provide a physical mechanism that underpins the effector selective mutations commonly employed to dissect Ral G protein function. Comparing the energetic landscape of the RalB-RLIP76 and RalB-Sec5 complexes reveals mutations in RalB that differentially bind the two effector proteins. A panel of RLIP76 mutants was used to probe the interaction between RLIP76 and RalA/B. Despite 100% sequence identity in the RalA/B contact residues with RLIP76, differences still exist in the energetic profiles of the two complexes.
Therefore we have revealed properties that may account for some of the functional separation observed with RalA and RalB at a cellular level. Our mutations, in both the Ral isoforms and RLIP76, provide new tools that can be employed to parse the complex biology of Ral G protein signalling networks. The combination of this thermodynamic and structural data can also guide efforts to ablate RalA/B activity with small molecules and peptides.
The Ral proteins are small G proteins that are activated downstream of Ras. There are two human Ral proteins, RalA and RalB, which despite having 82% sequence identity at the amino acid level have distinct cellular functions. Both proteins have roles in the regulation of cytokinesis. RalA acts first to secure the exocyst complex to the cytokinetic furrow; this is followed by RalB activity, which engages the exocyst at the midbody of the cytoplasmic bridge to drive abscission 1 . RalB has been demonstrated to promote autophagocytosis 2 , while RalA controls mitochondrial fission at mitosis 3 . Both Ral proteins also have roles in targeted exocytosis, receptor mediated endocytosis and the regulation of the actin cytoskeleton and while individual roles have not been assigned to
RalA and RalB in these processes, it seems likely they will emerge. In fact some specific roles are already known, for example, RalA drives polarized exocytosis in epithelial cells 4 , whereas RalB controls exocytosis during polarized cell migration 5 . Distinctive roles have also been assigned to RalA and RalB in the disease state: RalA is required for anchorage-independent proliferation in cancer cell lines, while RalB is necessary for tumour cells to avoid apoptosis 6 .
In common with most other small G proteins, the Ral proteins are found in two forms. When bound to GDP, they are inactive but when bound to GTP, they adopt their active conformation and can engage with downstream effector proteins, initiate signalling cascades and control cellular outcomes. The functional individuality of RalA and RalB is even more surprising considering they interact with the same set of downstream effector proteins and therefore share control of the same collection of signalling pathways 7 . Proposals for the mechanism underlying the specific actions of the Ral proteins in the absence of differential sets of effector proteins include distinctive cellular localization and divergent activation. The active conformation of small G proteins is based around two regions of the protein, known as switch 1 and switch 2, which are sensitive to the presence of the terminal phosphate in GTP. These switch regions mediate the majority of contacts with the effector proteins. RalA and RalB are identical in the switch regions, and most of the variation between the two proteins lies at their C-termini, beyond the structured G domain, in the residues that comprise the 'hypervariable region' 8 . In most small G proteins, this region controls membrane We have previously solved the structure of the complex that forms between RalB and the RLIP76 RBD 20 . We have now used this structure to design mutants of both RalB and RLIP76 to elucidate the thermodynamics of the binding interface produced by the two proteins interacting. In addition,
we have used the panel of RalB mutants that we generated to probe the interaction between RalB and a second effector protein, Sec5. Comparing the energetic landscape of the two complexes has revealed mutations in RalB that differentially bind the two effector proteins. We have also used the RLIP76 mutants to probe the interaction between RLIP76 and RalA to compare the energetics of the RalA and RalB complexes. Despite 100% sequence identity in the RalA/B contact residues for RLIP76, differences still exist in the energetic profiles of the two complexes.
Methods

Protein Expression Constructs
Simian RalA C (residues 1-184) was amplified by PCR and cloned into pMAT10 (DO, (393-446) was amplified by PCR and cloned into modified pGEX-His-2 using BamHI and XhoI restriction sites that had been incorporated into the PCR primers. The resulting construct expressed GST-RLIP76 RBD with a C-terminal His tag. The C411S mutation was introduced as described below. The construct was expressed in E. coli BL21 (Invitrogen). The Sec5 RBD expression construct has been described elsewhere 22 .
Recombinant Protein Production
A stationary culture containing pMAT10-RalA C was diluted 1 in 10 into 2TY and grown to an A stationary culture of each RLIP76 RBD construct was diluted 1 in 10 into 2TY, grown to an A 600 of ~0.8 at 37 °C, induced with 0.1mM IPTG and grown for a further 5h at 37 °C. Cells were lysed and the fusion protein purified using glutathione agarose (Sigma-Aldrich) following manufacturer's instructions. The fusion protein was cleaved with thrombin to remove the GST tag and further purified by gel filtration (S30 16/60, GE Healthcare). An accurate concentration of each protein was determined using amino acid analysis by the Protein and Nucleic Acid Chemistry Facility, Dept. Biochemistry, University of Cambridge. This protein was then used directly in SPAs. Purification of the Sec5 RBD has been published previously 22 .
Mutagenesis of the RLIP76 RBD
Mutations were introduced, as specified, into the coding region of RLIP76 RBD using the 
Nucleotide Exchange
Ral proteins were labelled with [ 3 H]GTP for use in binding assays as described previously 22 .
Scintillation Proximity Assays (SPA)
Affinities of Ral proteins for the RLIP76 RBD-His domain and its variants were measured using 
Results
Binding affinity of RLIP76 RBD for Ral isoforms
Previously we had measured the affinity of the RLIP76 RBD for both RalA and RalB and found that the two Ral isoforms interacted with similar affinities (our unpublished data and 20 ). We The C-terminal tail of the Ral proteins, as with most small G proteins, is thought to direct membrane localization in the cell. As such it is usually unavailable for effector binding, although
we have previously identified a role for the C-terminal polybasic region from one small G protein (Rac1) in effector binding 24 . These data indicate that full-length RalA and RalA C bind with equivalent affinity to RLIP 76 and Sec5. RalA C and RalB C also bind with similar affinities to each effector protein. We decided to proceed with a comparative study of RalA C and RalB C binding to RLIP76 to look for thermodynamic differences in the two Ral-RLIP76 complexes.
Thermodynamic mapping of the RLIP76 and Sec5 binding surfaces on RalB
The structures of Ral proteins in complex with the RLIP76 and Sec5 Ral binding domains 25, 26 provided the starting points for mapping the energetics of the interface between RalB and these effectors. We analysed the interfaces of the complexes (PDB codes 1UAD and 2KWI) to identify residues on the small G protein that were within 4Å of an effector residue and mutated these to alanine in RalB. There are two sidechains in RalB that interact with these effectors that are already alanine: Ala48 and Ala77. Ala48 contacts both RLIP76 and Sec5 and was changed to Gly, so that the requirement for the alanine methyl group could be probed. Ala48 lies within switch 1, which is unstructured and highly flexible in active RalB, so substitution with a glycine is unlikely to affect the secondary structure. Ala77 is within a helix in switch 2 in RalB and interacts with His413 and various hydrophobic residues in RLIP76. We therefore mutated it to a larger, charged residue (Arg). Other mutations were also made as follows. Tyr36 forms a hydrogen bond in both Sec5 and RLIP76 complexes, so we mutated it to Phe, reasoning that this would remove the hydroxyl group, while maintaining the bulky aromatic ring. Glu38 forms a salt bridge with Arg27 in the Sec5 complex, so we mutated it to Gln, hence removing the charge but maintaining the size of the sidechain. Two mutations were made to Thr46, although this residue does not interact directly with either effector. Thr46 is equivalent to Ras Thr35, whose mutation to Ser prevented Ras binding to RalGDS and PI3K but not to Raf 27, 28 . The T46S mutant is the direct equivalent and was tested to investigate whether this mutation would discriminate between RLIP76 and Sec5. The T46A mutation was also generated, to study the effect of removing the hydroxyl group completely.
Finally, the D49E mutation was generated because this is mutant is known to prevent binding to Sec5 but not to RLIP76 in yeast two-hybrid experiments 29 . This therefore allowed an assessment of whether the in vitro affinity measurements correlate with the effects of this mutation in a (yeast) cell.
The apparent K d values for the interaction between the RalB mutants and the RLIP76 and Sec5
RBDs were determined by SPA. Selected binding isotherms are shown in Figure 2A and 2B and the affinities are summarized in Table 2 .
Mutations that reduce the binding between RLIP76 RBD and RalB include Y36A, T46A, T46S, D49A, Y51A, L67A, Y82A and R84A, which decrease the affinity more than 10-fold, mutations E38A and E73A, which decrease the affinity between 5 and 10-fold and mutations E38Q, A48G, R52A, I78A and N81A, which all decrease the affinity between 3 and 5-fold. Interestingly one mutation, S50A, shows a small increase in binding affinity for RLIP76. Thus Tyr36, Thr46, Asp49, Tyr51, Leu67, Glu73, Tyr82 and Arg84 all contribute at least 1.2kcal/mol to the interface, with Tyr51 and Tyr82 making the largest individual contributions.
Mutations Y36A/F, E38A/Q, T46A/S, D49E and Y51A all effectively abrogate binding to Sec5, mutations L14A, K47A and L67A all decrease the affinity for Sec5 between 3 and 7-fold.
Mutations at other residues show only a minor effect or no change in the binding affinity. Mutation D49A shows a small increase in binding affinity for Sec5.
Thermodynamic mapping of the RalA and RalB binding surfaces on the RLIP76 RBD
Having investigated the differences in thermodynamics between a Ral protein and two of its effector proteins, we next wanted to extend our studies to see if there were any differences in the energetic contributions of an effector protein for the two Ral proteins. RalA and RalB have 82% sequence identity but are 100% identical across the residues that contact RLIP76 20 so we next investigated the energetic contributions of sidechains on the RLIP76 RBD to binding to the Ral small G proteins. In a similar manner to our dissection of the RalB interaction surface, we identified sidechains of RLIP76 residues that were within 4Å of a RalB sidechain in our RalB-RLIP76 RBD structure and mutated them to alanine. The apparent K d values for the interaction between the RLIP76 RBD mutants with RalB were determined by SPA. Selected binding isotherms are shown in Figure 3A and the affinities are summarized in Table 3 .
Substitution of RLIP76 residues His413, Trp430 and Thr437 with alanine ablated the binding to RalB, alanine substitutions of Leu409, Leu429 and Lys440 reduced the affinity significantly (16.5, 22.8 and 8.8-fold respectively) and substitution of Leu416 with alanine reduced the affinity 4.7-fold. Mutations at the remaining residues tested had deleterious effects on RalB binding but to a lesser extent and were thus considered to be individually insignificant. Exceptionally, introducing the Q417A mutation into the RLIP76 RBD enhanced binding to RalB by more than 2-fold.
We then tested the same panel of RLIP76 RBD mutants for their ability to bind RalA. Selected binding isotherms are shown in Figure 3B and the affinities are summarized in Table 3 . Similarly to RalB, mutation to alanine at residues Leu409, His413, Trp430, Thr437 and Lys440 all decrease binding by ~9-fold or more. Mutation at residue Leu416 decreased the affinity 9-fold, which is larger than the reduction in affinity for RalB for this mutation, while mutation at Leu429 reduced the affinity by 5.6-fold, significantly less than the effect on RalB affinity. Mutating Arg434 to alanine abrogated binding to RalA but had very little effect (2-3-fold reduction) on RalB. The remaining residues, when mutated, all had a small detrimental affect on binding to RalA and were not considered to be significant, except Q433A, which had no affect on RalA binding. There were no mutations that increased the binding of RalA.
Residues Leu409, His413, Leu429, Trp430, Thr437 and Lys440 all contribute >1.2 kcal/mol to the RLIP76-RalB interface. Residues Leu409, His413, Leu416, Tyr430, Arg434, Thr437 and Lys440 of RLIP76 all contribute >1.2 kcal/mol to the RLIP76-RalA interface.
Discussion
Using our structure of RalB bound to the RLIP76 RBD 20 and the structure of RalA bound to Sec5 26 , we have designed mutations to probe the thermodynamics of the binding interfaces and dissect the energetic contributions of specific RalB residues for these two effector proteins. Figures   4A and 4B show heat maps for the RLIP76 and Sec5 binding surfaces on RalB. It is immediately striking that the energetically important binding surface for RLIP76 is much more extensive than that for Sec5. This is not surprising, since a comparison of the Ral complex structures reveals that the effectors themselves are strikingly different, as are the regions that they contact on the Ral proteins ( Figures 4C and 4D ). The Sec5 RBD has an all sheet, Ig-like fold, which forms an intermolecular antiparallel  sheet with the 2 strand of RalA, interacting exclusively with residues in and around switch 1 and burying ~1000 Å 2 in the interface 26 . The RLIP76 RBD-RalB structure 20 shows that the RLIP76 RBD forms a simple coiled-coil, which interacts with both switch 1 and switch 2 in RalB and buries ~1700 Å 2 . It is logical, therefore that we find residues with significant energetic input into RalB-RLIP76 complex formation across RalB switches 1 and 2. For Sec5 the highest energetic contributions are exclusively found from residues in switch 1 of RalB. These thermodynamic differences highlight certain RalB residues that if mutated would differentially discriminate between effectors. For example, RalB Y82A or D49A mutants would no longer bind to RLIP76 but would retain the ability to bind to Sec5. Conversely RalB Y36F or D49E should retain the ability to bind RLIP76 but no longer be competent to bind Sec5. Such mutations should be useful tools to dissect Ral effector pathways in vivo. In fact the affinities of the D49E mutant that we have quantified in vitro are in agreement with the results found for this mutation by yeast two-hybrid and by co-immunoprecipitation in HEK293T cells 29 . Thus all of the mutants that we describe here are likely to have the same effects in vivo as we have seen in vitro.
Some of the residues whose mutation affects binding are not involved in directly contacting the effector but play a supporting role in maintaining the structure of the RalB interacting residues. For example, in both complexes Thr46 makes no direct contact with the effectors (Figure 4C , 4D) but its mutation to Ser or Ala reduces the binding to both significantly. As this Thr residue contacts the Mg 2+ ion in the RalB protein it is not surprising that the integrity of the switch regions is compromised. The T46A/S mutants can still, however be loaded with the GTP-analogue and T46S
shows some affinity for RLIP76. Similarly, Leu67, which is close to the interface in both complexes, forms hydrophobic contacts in RLIP76 but not in Sec5. In the latter it still has a small effect on binding, presumably because it supports the RalB 2 strand, which is involved in an intermolecular -sheet with Sec5 ( Figure 4D ). This is also the case for Leu14, which is within 1
and packs next to Leu67. Leu14 reduces Sec5 binding but not RLIP76 binding, highlighting the importance of the intermolecular -sheet in the Sec5 interaction. There are also supporting residues in the RalB-RLIP76 interaction whose mutations affect binding. The E38A mutant knocks out Sec5 binding and reduces RLIP76 binding. In the Sec5 complex Glu38 forms a salt bridge with Sec5 residue Arg27 but Glu38 does not contact RLIP76 directly. Instead, it is likely to be involved in maintaining the position of the neighbouring residue, Tyr36, which does contact RLIP76. It is possible that replacing the charged Glu38 with the smaller, hydrophobic Ala allows the 1 helix to be extended to residue 38, altering its conformation and that of switch 1. This is consistent with the observation that the E38Q mutation has a lesser effect on binding of RLIP76, since Gln38 is not charged but is more polar than Ala. A similar argument may explain the effect of the E73A mutant, which reduces the binding of RLIP76 5-fold. Glu73 is next to the switch 2 helix, 2, and its mutation to Ala is likely to alter 2 and therefore the ability of residues in this helix to contact RLIP76.
Some of the mutations that we have tested here have previously been generated in RalA and their effects on Exo84 and Sec5 measured 30 . The effects on Sec5 binding were broadly consistent with our observations on the RalB-Sec5 interaction, for example, the E38A mutation did not affect Exo84 binding but reduced the affinity for Sec5 ~45-fold just as in RalB (Table 1 ). The R52A mutant of RalA bound to Sec5, with a similar affinity to wild-type, similar to its effects in RalB, but reduced the affinity of Exo84 18-fold. Arg52 forms a hydrogen bond in the RalA-Exo84 complex so the effects of this mutation can be explained.
We next resolved the contribution of RLIP76 residues to complex formation with RalA and RalB.
Figures 5A and 5B show the energetically important residues on RLIP76 for RalA and RalB binding. It is striking that although the residues in RalB that contact RLIP76 are 100% conserved in RalA, the binding hotspots on RLIP76 are not identical (Table 3) helix at the C-terminus of switch 2 ( Figure 5C ). Any changes in switch 2 would also be readily transmitted to the 1 and 2 strands, which lie underneath switch 2. Hence, the changes in the 3-5 loop sequence and length may be responsible for the differences in contribution of residues in switch 2 (Ala77, Asn81, Tyr82) and the 1/2 strands (Lys16, Asp65) to interactions with RLIP76 Leu429 and Arg434. For the purposes of this discussion, we have assumed that Leu429 and Arg434 contact broadly the same residues in RalA as in RalB, which is likely although not certain in the absence of a RalA-RLIP76 structure.
Interestingly substitution of one residue, Gln417, with Ala had little affect on RalA binding but slightly increased (2.2-fold) the affinity of the RalB complex. This residue also contacts RalB switch 2, via the sidechain of Tyr75. The effects of this mutation therefore also supports the idea that switch 2 is subtly different in the RalA and RalB isoforms. This is in agreement with our NMR analysis, which suggests that switch 2 has some differences in msec timescale dynamics in the two Ral proteins (manuscript in preparation).
A number of the mutations that we have identified are likely to mediate their effects on binding via medium range structural rearrangements. Allostery in GTPases has been observed in several situations and its exploitation is becoming increasingly important for targetting these proteins.
Binding of calcium acetate to helix3-loop7 of Ha-Ras, in a crystallized form, results in structural rearrangements that ultimately order the N-terminal region of switch II and position Glu61 in the active site 31 . Identification of a unique pocket in the Ki-Ras G12C oncogenic variant prompted screening for binding compounds. This pocket is adjacent to the nucleotide binding site and binding compounds have been identified that change the nucleotide affinity leading to a preference for GDP over GTP and simultaneously block GEF activation using an allosteric mechanism 32 . A region adjacent to but distinct from the nucleotide binding site has also been utilized to target inhibitors to the Ral GTPases. Again binding to this allosteric site is sufficient to modulate GTPase activity in vitro and in vivo 33 . Dynamic exchange between different conformations is also well documented in small G proteins. NMR has shown that Ha-Ras bound to GTP or GTP analogues exhibits dynamics on a msec timescale 34, 35 . Furthermore, 31 P NMR experiments suggested the presence of multiple conformations in active forms of small GTPases 22, 36 . Taken together these studies demonstrate the importance of conformational and structure flexibility to small G protein function and also establish the utility of this feature as a means of attacking these proteins therapeutically.
In summary, our hotspot analysis of the binding of RLIP76 to RalA and RalB suggests that at least some of the differences in the Ral proteins lie in the structure and dynamics of switch 2 and the consequences for effector binding that ensue. We have identified some residues of RLIP76 that can be mutated to prevent its binding to both RalA and RalB e.g. His413 and Trp430. Furthermore, we have identified two residues whose mutation will allow discrimination between the Ral isoforms:
the L429A mutation will reduce RalB binding significantly more than RalA binding, while the R434A mutation abrogates RalA binding but has little effect on RalB binding. These mutants represent essential tools for dissecting the roles of RalA and RalB in vivo. RalB is shown as a red sphere.
